Sodium Succinate (1 brand name, 1 dosage form, 1 route)
Available dosage forms: INJECTABLE.
Routes of administration: INJECTION.
Brand Names
- SODIUM SUCCINATE
Related Health Topics
Indications and Usage
When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of Methylprednisolone Sodium Succinate for Injection, USP, is indicated as follows:
Dosage and Administration
NOTE: Methylprednisolone Sodium Succinate for Injection contains benzyl alcohol (see DESCRIPTION, WARNINGS and PRECAUTIONS, Pediatric Use). Because of the possible physical incompatibilities, Methylprednisolone Sodium Succinate for Injection should not be diluted or mixed with other solutions. Use only the Bacteriostatic Water For Injection with Benzyl Alcohol when reconstituting Methylprednisolone Sodium Succinate (see DESCRIPTION ). Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. This preparation may be administered by intravenous injection, by intravenous infusion, or by intramuscular injection, the preferred method for initial emergency use being intravenous injection. Following the initial emergency period, consideration should be given to employing a longer acting injectable preparation or an oral preparation. There are reports of cardiac arrhythmias and/or cardiac arrest following the rapid administration of large IV doses of Methylprednisolone Sodium Succinate (greater than 0.5 gram administered over a period of less than 10 minutes). Bradycardia has been reported during or after the administration of large doses of Methylprednisolone Sodium Succinate, and may be unrelated to the speed or duration of infusion. When high dose therapy is desired, the recommended dose of Methylprednisolone Sodium Succinate Sterile Powder is 30 mg/kg administered intravenously over at least 30 minutes. This dose may be repeated every 4 to 6 hours for 48 hours. In general, high dose corticosteroid therapy should be continued only until the patient’s condition has stabilized; usually not beyond 48 to 72 hours. In other indications, initial dosage will vary from 10 to 40 mg of methylprednisolone depending on the specific disease entity being treated. However, in certain overwhelming, acute, life-threatening situations, administrations in dosages exceeding the usual dosage
Contraindications
Methylprednisolone Sodium Succinate sterile powder is contraindicated: In systemic fungal infections and patients with known hypersensitivity to the product and its constituents; For intrathecal administration. Reports of severe medical events have been associated with this route of administration. Intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura. The use of Methylprednisolone Sodium Succinate for Injection is contraindicated in premature infants because when reconstituted will contain benzyl alcohol. (See WARNINGS and PRECAUTIONS: Pediatric Use)
Adverse Reactions
The following adverse reactions have been reported with Methylprednisolone Sodium Succinate or other corticosteroids:
Drug Interactions
This section is empty. No content has been added.
Overdosage
Treatment of acute overdosage is by supportive and symptomatic therapy. For chronic overdosage in the face of severe disease requiring continuous steroid therapy, the dosage of the corticosteroid may be reduced only temporarily, or alternate day treatment may be introduced.